Category | Clinical Trial Services
The continued growth of groundbreaking advanced therapies owes part of its success to the meticulous collection, preservation, and utilization of highly valuable but temperature-sensitive biological materials, and biorepositories serve an invaluable role in the preservation of these critical materials.
As biopharma companies advance through their research and clinical trials, they may ask themselves an important question: should we build or buy a biorepository?
The answer can be quite complex and varies from organization to organization. After all, every research project has its own unique goals. Additionally, collections of biological materials can differ tremendously in size, scope, handling constraints, and storage requirements.
When weighing the benefits and drawbacks of building vs. buying a biorepository, it’s essential to understand what’s most important: maintaining control over every aspect of sample storage or saving time, money, and human resources.
Establishing a biorepository in-house provides greater control and ownership over the entire process, allowing biopharma companies to tailor the biorepository to their specific needs, which helps to ensure high-quality storage conditions and maintain strict governance over samples. However, the initial set-up costs can be considerable, involving investments in state-of-the-art equipment, skilled staff, and dedicated infrastructure — not to mention the ongoing costs for normal operations and potential future expansions.
In this post — the first in a two-part series — we examine the pros and cons of building a biorepository. Part two of the series considers the advantages and disadvantages associated with buying a biorepository.
Ultimately, the decision to build a biorepository should be based on a careful assessment of the biopharma company’s current resources, research goals, budget constraints, and project timelines. While building provides customization and control, it comes with higher upfront costs and time commitments. Conversely, buying a biorepository offers convenience and potential cost savings but may limit customization and control. Many organizations choose a hybrid approach, where they build some infrastructure but also partner with CDMOs to leverage their expertise and capabilities.